dose
mgkg
could
protect
test
rat
lethal
dose
letx
even
administr
mgkg
h
letx
challeng
protect
test
rat
result
indic
potenti
candid
clinic
applic
anthrax
treatment
bacterium
bacillu
anthraci
primarili
affect
livestock
also
infect
human
caus
agent
anthrax
zoonot
diseas
bioterror
threat
b
anthraci
spore
use
bioterror
agent
biolog
warfar
threat
spur
signific
effort
toward
develop
countermeasur
anthrax
includ
anthrax
vaccin
therapeut
howev
vaccin
effect
prevent
current
therapeut
antibodi
target
anthrax
toxin
develop
design
protect
diseas
b
anthraci
secret
tripartit
toxin
compris
protect
antigen
pa
lethal
factor
lf
edema
factor
ef
ab
binari
bacteri
toxin
pa
b
subunit
respons
cell
surfac
bind
lf
ef
subunit
respons
enzymat
activ
toxin
pa
combin
lf
ef
constitut
lethal
toxin
letx
edema
toxin
edtx
respect
first
step
cellular
intox
involv
bind
kd
form
pa
specif
cell
surfac
receptor
follow
receptor
bind
cleav
arglyslysarg
sequenc
amino
acid
posit
furinfamili
proteas
result
kda
form
spontan
oligomer
either
heptam
octam
dissoci
kda
form
allow
bind
either
ef
lf
oligomer
complex
transloc
lf
ef
cytosol
promot
intox
previou
studi
shown
insert
stabli
irrevers
lipid
bilay
form
ionperm
channel
research
shown
proteas
cleavag
site
delet
mutat
prevent
ef
lf
bind
cell
treat
lysosomotrop
agent
abil
pa
mediat
action
ef
lf
block
nasal
immun
mice
mixtur
lf
dglutam
acid
conjug
shown
exhibit
strong
antibodi
respons
three
antigen
thu
seem
ideal
target
fragment
antibodi
gener
select
sinc
passiv
immun
protect
antibodi
provid
immedi
extens
protect
independ
host
respons
attract
option
enhanc
current
postexposur
treatment
anthrax
especi
regard
biodefens
consid
primari
avail
therapeut
measur
past
year
extens
research
focus
develop
therapeut
antibodi
target
main
virul
factor
anthrax
name
pa
lf
ef
capsul
among
pa
play
central
role
pathophysiolog
anthrax
excel
therapeut
target
import
part
pa
present
studi
develop
murin
igg
neutral
antibodi
directli
target
select
ideal
antibodi
among
genet
recombin
form
humanmurin
chimer
igg
code
could
specif
bind
protect
cell
letx
challeng
vitro
protect
fischer
rat
letx
challeng
elisa
perform
test
bind
sensit
recogn
dosedepend
manner
graph
concentr
absorb
nm
hyperbol
curv
fig
western
blot
analysi
show
could
specif
recogn
fig
reaction
seen
neg
control
immunoprecipit
immunoprecipit
perform
use
could
split
activ
use
trypsin
protein
kda
detect
sdspage
sequenc
match
b
anthraci
protect
antigen
swissprot
databas
fig
c
kda
membran
protein
also
detect
use
commerci
antipa
antibodi
fig
protein
reaction
antibodi
kinet
bind
equilibrium
dissoci
constant
kd
determin
analysi
rate
constant
kon
koff
evalu
directli
sensogram
kd
also
determin
use
one
strike
featur
slow
rate
may
explain
high
affin
fig
vitro
letx
neutral
assay
abil
protect
letx
assess
cell
differ
concentr
lf
simultan
ad
cell
cell
viabil
test
result
indic
could
complet
neutral
letx
gml
lf
gml
cell
remain
viabl
control
igg
antibodytr
cell
remain
viabl
gml
lf
gml
cell
viabl
fig
control
cell
protect
rat
rat
inject
antibodi
via
tail
vein
either
letx
inject
surviv
time
group
iii
significantli
p
longer
group
ii
last
observ
group
iv
rat
aliv
fig
rat
inject
min
letx
show
similar
result
dose
g
antibodi
protect
rate
death
fig
although
symptom
acceler
breath
lethargi
observ
one
rat
inject
letx
administr
protect
rat
develop
anthrax
fig
prophylact
function
test
inject
antibodi
differ
time
letx
inject
group
receiv
prophylaxi
min
h
letx
inject
rat
remain
aliv
fig
inject
pa
protect
rat
anthrax
death
regardless
lf
inject
time
fig
tissu
patholog
immunohistochem
analysi
lung
rat
patholog
immunohistochem
examin
h
e
stain
show
local
tissu
rat
inject
letx
show
greater
alveolar
exud
fig
untreat
control
rat
fig
howev
group
receiv
letx
g
fig
show
signific
differ
untreat
control
rat
sinc
anthrax
receptor
express
cell
includ
alveolar
epitheli
cell
cell
bind
pa
could
posit
rat
inject
letx
cell
could
dectect
pa
posit
stain
mainli
local
membran
strong
posit
reaction
found
group
inject
letx
fig
weak
posit
reaction
found
group
inject
letx
g
fig
untreat
control
group
show
neg
reaction
fig
studi
reveal
two
major
find
first
humanmurin
chimer
antibodi
neutral
letx
vivo
use
prohylaxi
letx
releas
blood
second
sinc
immun
produc
neutral
antibodi
use
immun
anim
present
studi
develop
four
murin
mab
could
well
neutral
letx
vitro
one
clone
select
form
humanmous
chimer
antibodi
known
antibodi
show
excel
neutral
vitro
vivo
current
statu
therapeut
mab
direct
major
virul
factor
pa
lf
ef
capsul
although
lf
could
induc
cell
death
effect
result
vivo
unsatisfactori
pa
critic
factor
recogn
cell
membran
receptor
pa
cleav
activ
furin
induc
lf
ef
cell
strategi
get
antibodi
activ
immun
mice
use
form
dissoci
instead
although
part
factor
may
differ
structur
expos
lfor
efbind
site
differ
may
turn
lead
product
complet
differ
antibodi
anthrax
vivo
present
studi
show
could
induc
neutral
antibodi
proven
vitro
vivo
experi
hand
difficult
obtain
activ
base
present
method
screen
posit
clone
activ
differ
way
base
tradit
elisa
coat
plate
aliv
cell
overninght
cell
cultur
condit
ad
well
incub
h
neg
control
cell
without
ad
rest
elisa
procedur
normal
screen
system
activ
close
vivo
state
could
oligomer
heptam
divers
antibodi
gener
immun
stage
effect
antibodi
obtain
screen
system
anthrax
whether
result
natur
bioterroristassoci
exposur
constant
threat
human
health
low
incid
anthrax
suggest
largescal
vaccin
may
effici
mean
control
diseas
passiv
immun
protect
antibodi
therefor
consid
primari
avail
biodefens
measur
especi
bioterroristassoci
exposur
present
studi
found
provid
good
protect
rat
challeng
anthrax
virul
factor
vitro
experi
maintain
cell
viabil
gml
lf
gml
noncorrel
igg
maintain
cell
viabil
gml
lf
gml
maintain
cell
viabil
control
antibodi
maintain
moreov
previou
studi
often
use
rat
challeng
letx
tabl
test
b
anthraci
spore
therefor
rat
inject
letx
vial
tail
vain
kd
nm
protect
rat
death
concentr
mgkg
g
per
rat
howev
previou
studi
mgkg
raxibacumab
human
origin
kd
nm
administ
h
anthrax
lethal
toxin
administr
rat
also
test
concentr
mgkg
g
per
rat
administ
h
letx
inject
dose
also
protect
rat
find
indic
may
use
prophylact
human
chimer
mab
examin
anim
model
affin
found
present
studi
better
found
previous
murin
mab
pa
develop
chimer
mab
maintain
balanc
highaffin
murin
compon
lowimmunogen
human
compon
mab
human
origin
avail
difficult
produc
expens
chimer
mab
produc
cell
method
product
conveni
vivo
test
present
studi
irrespect
whether
lf
inject
antibodi
protect
rat
death
provid
administ
simultan
pa
find
indic
could
prevent
lf
bind
morpholog
chang
observ
rat
inject
letx
probabl
time
inject
sacrific
short
min
histolog
chang
occur
period
ihc
analysi
show
strong
posit
result
group
inject
letx
howev
group
receiv
letx
g
show
weakli
posit
reaction
find
indic
prevent
pa
bind
cell
receptor
howev
experi
requir
valid
hypothesi
futur
studi
focu
detail
character
mab
specif
toxic
studi
autoantigen
test
etc
second
epitop
map
structur
function
analysi
perform
vivo
experi
present
studi
demonstr
could
interfer
lf
bind
pa
experiment
need
determin
exact
mechan
neutral
letx
lastli
anim
test
requir
exampl
anim
challeng
anthrax
spore
summari
report
humanmurin
chimer
igg
name
specif
identifi
pa
high
affin
neutral
letx
protect
macrophag
rat
anthraxrel
death
also
show
good
immunogen
find
believ
character
use
alon
combin
neutral
mab
treatment
anthrax
use
pcoldii
vector
purifi
affin
chromatographi
six
balbc
mice
age
week
intraperiton
ip
immun
adjuv
describ
previous
immun
mous
spleen
show
best
titer
remov
splenocyt
extract
fuse
myeloma
cell
use
hybridoma
technolog
posit
clone
screen
elisa
use
activ
plate
subclon
conduct
base
standard
protocol
clonal
expans
conduct
hybridomasfm
gibco
usa
cell
supernat
remov
purifi
affin
chromatographi
protein
g
ge
usa
accord
manufactur
purif
system
figur
vivo
letx
neutral
assay
rat
mean
surviv
time
letx
antibodi
simultan
inject
via
tail
vein
group
g
g
letx
group
ii
g
g
letx
group
iii
g
g
letx
group
iv
g
g
letx
p
b
differ
concentr
antibodi
inject
letx
inject
min
later
via
tail
vein
c
rat
g
antibodi
inject
min
min
simultan
min
letx
rat
g
antibodi
inject
differ
time
letx
inject
e
group
pa
g
inject
min
lf
g
g
group
ii
pa
g
inject
min
lf
g
g
experi
involv
anim
perform
accord
protocol
approv
anim
care
use
committe
nation
institut
allergi
infecti
diseas
nation
institut
health
usa
total
rna
extract
hybridoma
cell
use
trizol
reagent
invitrogen
cdna
synthes
use
revers
transcriptas
superscript
ii
accord
manufactur
instruct
eukaryot
vector
construct
separ
clone
heavi
light
variabl
region
pth
ptl
respect
includ
constant
region
heavi
light
chain
murin
variabl
region
heavi
v
h
light
chain
v
l
first
amplifi
pcr
use
cdna
templat
obtain
v
h
v
l
nucleotid
sequenc
chain
clone
vector
pcr
primer
design
use
infusionr
hd
clone
kit
clontech
v
h
v
l
amplifi
rightsequenc
vector
use
primer
final
v
h
v
l
separ
clone
linear
pth
ptl
vector
respect
infus
pcr
use
infusionr
hd
clone
kit
recombin
elisa
ninetysixwel
enzym
immunoassay
plate
coat
overnight
l
antigen
gml
dilut
mm
sodium
carbon
buffer
ph
plate
block
serial
twofold
dilut
ad
well
well
concentr
primari
antibodi
plate
incub
h
wash
time
l
pb
contain
tween
pbst
subsequ
goat
antihuman
igghrp
conjug
sigma
ad
secondari
antibodi
incub
min
color
develop
absorb
valu
well
detect
nm
noncorrel
use
control
absorb
valu
nm
plot
use
graphpad
prism
softwar
version
graphpad
softwar
inc
la
jolla
ca
usa
cell
lysat
recombin
bacteria
e
coli
separ
run
sdspage
gel
transfer
onto
nitrocellulos
membran
biorad
membran
block
pb
contain
dri
milk
overnight
incub
h
rt
dilut
mgml
stock
wash
time
pbst
membran
incub
dilut
secondari
hrpconjug
goat
antihuman
antibodi
sigma
addit
min
rt
follow
wash
procedur
signal
detect
use
ecl
western
blot
substrat
pierc
accord
manufactur
instruct
ph
mm
nacl
gml
trypsin
sigma
min
follow
addit
gml
soybean
trypsin
inhibitor
sigma
mixtur
incub
g
rotat
h
next
l
proteina
sepharos
invitrogen
usa
ad
incub
immun
complex
form
wash
time
pbst
subsequ
l
elut
buffer
ad
separ
antibodyantigen
complex
proteina
sepharos
neg
control
anoth
chimer
antibodi
gener
lab
creat
use
protocol
protein
complex
isol
run
two
sdspage
gel
one
transfer
onto
nitrocellulos
membran
stain
coomassi
blue
nitrocellulos
membran
block
overnight
incub
dilut
rabbit
polyclon
antipa
antibodi
pierc
usa
h
rt
wash
pbst
time
react
dilut
goat
antirabbit
igghrp
conjug
sigma
addit
min
rt
membran
wash
time
pbst
hybrid
signal
detect
use
ecl
western
blot
substrat
target
band
sdspage
gel
subject
mass
spectra
identif
abi
proteom
analyz
malditoftof
mass
spectromet
appli
biosystem
framingham
mass
spectra
search
within
swissprot
databas
use
mascot
search
engin
http
wwwmatrix
sciencecom
matrix
scienc
uk
affin
kinet
assay
antibodi
biacor
system
ge
usa
use
analyz
affin
kinet
antibodi
dilut
gml
acet
buffer
mm
naac
ph
immobil
surfac
sensor
chip
ge
usa
captur
purifi
mab
dilut
run
buffer
mm
hepe
mm
nacl
mm
edtana
ph
achiev
differ
concentr
rang
nmoll
associ
time
set
dissoci
time
follow
regener
mm
glycinehcl
ph
sensogram
evalu
use
biacor
evalu
softwar
vitro
letx
neutral
assay
vitro
letx
neutral
assay
perform
describ
previous
inject
via
tail
vein
mixtur
pa
lf
letx
differ
amount
antibodi
prepar
steril
pb
rat
administ
l
mixtur
rat
also
treat
differ
concentr
antibodi
min
exposur
letx
experi
inject
intraven
pb
g
antibodi
receiv
intraven
inject
letx
g
pa
g
lf
addit
doubl
complet
protect
dose
antibodi
g
inject
test
prophylact
abil
rat
inocul
g
antibodi
follow
letx
administr
differ
time
min
h
two
addit
experi
conduct
rat
one
group
receiv
pa
g
inject
min
lf
g
g
respect
receiv
g
pa
min
lf
dose
inject
letx
sign
malais
death
check
everi
min
first
h
h
h
follow
twicedaili
check
week
tissu
patholog
immunohistochem
examin
lung
rat
embed
paraffin
wax
depart
patholog
nanj
medic
univers
jiangsu
china
use
routin
method
section
deparaffin
xylen
dehydr
decreas
concentr
alcohol
section
treat
h
e
stain
examin
light
microscopi
determin
patholog
featur
lung
tissu
remain
section
endogen
peroxidas
activ
block
incub
hydrogen
peroxidas
trisbuff
salin
tissu
section
incub
rabbit
polyclon
antipa
primari
antibodi
pierc
usa
follow
envis
hrp
complex
dako
carpinteria
ca
counterstain
hematoxylin
qs
vector
laboratori
burlingam
ca
result
analyz
accord
ihc
score
ih
describ
previous
briefli
ih
determin
evalu
stain
densiti
intens
multipl
intens
percentag
score
yield
final
ih
sampl
ih
consid
weakli
posit
ih
consid
strongli
posit
ihc
result
evalu
two
independ
investig
blind
rat
group
case
conflict
pathologist
review
case
consensu
reach
surviv
data
analyz
use
graphpad
prism
version
statist
analysi
softwar
san
diego
ca
ttest
use
compar
mean
surviv
time
group
twotail
log
rank
test
use
determin
statist
signific
differ
group
p
valu
consid
statist
signific
